Poland· PL-100416690

Delstrigo

A lamivudine, tenofovir disoproxil and doravirine product containing doravirinum + lamivudinum + tenofovirum disoproxilum, registered in Poland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 13 of our 19 countries.

ATC J05AR24

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedDelstrigoATCJ05AR24REGISTER NO.PL-100416690PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Lamivudine, tenofovir disoproxil and doravirine is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AR24 (lamivudine, tenofovir disoproxil and doravirine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Lamivudine, tenofovir disoproxil and doravirine · ATC J05AR24

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Doravirinum + Lamivudinum + Tenofovirum disoproxilum
Manufacturer
Merck Sharp & Dohme B.V.
Country
Poland (PL)
ATC code
J05AR24
ATC class
Lamivudine, tenofovir disoproxil and doravirine
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    00191778021578

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Lamivudine, tenofovir disoproxil and doravirine in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lamivudine, tenofovir disoproxil and doravirine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Delstrigo
  • Liechtenstein · Delstrigo
  • Norway · Delstrigo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/072e1681-c6d9-49ee-aaa9-4948919c7cde
GET /v1/drugs/072e1681-c6d9-49ee-aaa9-4948919c7cde?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "100 mg + 300 mg + 245 mg",
  "packaging": "00191778021578 ¦ Rpz ¦ EU/1/18/1333/001 ¦ 131314\n30 tabl.\nRpz ¦ EU/1/18/1333/002 ¦ 131315\n90 tabl. (op. zbiorcze)",
  "substance": "Doravirinum 100 mg + Lamivudinum 300 mg + Tenofovirum disoproxilum 245 mg",
  "common_name": "Doravirinum + Lamivudinum + Tenofovirum disoproxilum",
  "pl_product_id": "100416690",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about lamivudine, tenofovir disoproxil and doravirine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.